A phase i study of ridaforolimus in adult Chinese patients with advanced solid tumors

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Liu, Lian ^a,b   Zhang, Wen ^a,b   Li, Wenhua ^a,b   Lv, Fangfang ^a,b   Xia, Zuguang ^a,b   Zhang, Sheng ^a,b   Liu, Wen ^c   Zandvliet, Anthe S ^c   Waajen, Sylvia ^c   Zhang, Li Xin ^c   Yan, Li ^c   Li, Jin ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adverse event; MTOR inhibitor; Pharmacokinetic analysis; Phase I study

Indexed keywords

RIDAFOROLIMUS;

ADULT; ANEMIA; APNEA; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSTIPATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; MALE; PHASE 1 CLINICAL TRIAL; PROTEINURIA; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SIROLIMUS;

EID: 84879833220     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-48     Document Type: Article

References (16)

1. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Yuan RR, Kay A, Berg WJ, Lebwohl D, J Hematol Oncol 2009 2 45 10.1186/1756-8722-2-45 19860903
2. Targeting mtor globally in cancer: thinking beyond rapamycin. Shor B, Gibbons JJ, Abraham RT, Yu K, Cell Cycle 2009 8 23 3831 3837 10.4161/cc.8.23.10070 19901542
3. The mtor pathway: a new target in cancer therapy. Ciuffreda L, Di Sanza C, Incani UC, Milella M, Curr Cancer Drug Targets 2010 10 5 484 495 10.2174/156800910791517172 20384580
4. Akt-dependent and -independent mechanisms of mtor regulation in cancer. Memmott RM, Dennis PA, Cell Signal 2009 21 5 656 664 10.1016/j.cellsig.2009.01. 004 19166931
5. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. Wang L, Shi WY, Wu ZY, et al. J Hematol Oncol 2010 3 30 10.1186/1756-8722-3-30 20828385
6. Ridaforolimus (AP23573; MK-8669), a potent mtor inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, et al. Mol Cancer Ther 2011 10 6 1059 1071 10.1158/1535-7163.MCT-10-0792 21482695
7. Safety and preliminary efficacy analysis of the mtor inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross ME, Clin Genitourin Cancer 2012 10 4 232 238 10.1016/j.clgc.2012.05.001 22695254
8. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, et al. J Clin Oncol 2012 30 1 78 84 10.1200/JCO.2011.35.6329 22067397
9. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, et al. Clin Cancer Res 2008 14 9 2756 2762 10.1158/1078-0432.CCR- 07-1372 18451242
10. Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results. Blay JY, Chawla SP, Ray-Coquard I, Cesne AL, Staddon AP, Milhem MM, et al. J Clin Oncol 2012 30 Suppl abstr 10010: http://meetinglibrary. asco.org/content/98836-114
11. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, et al. J Clin Oncol 2008 26 3 361 367 10.1200/JCO.2007.12.0345 18202410 (Pubitemid 351171685)
12. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, et al. Clin Cancer Res 2009 15 4 1428 1434 10.1158/1078-0432.CCR-08-2076 19228743
13. Phase I study for ridaforolimus, an oral mtor inhibitor, in japanese patients with advanced solid tumors. Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, et al. Cancer Chemother Pharmacol 2012 69 4 1099 1105 10.1007/s00280-011-1788-4 22143378
14. Deforolimus trial 106: a phase I trial evaluating 7 regimens of oral deforolimus (AP23573; MK-8669). Mita MM, Britten CD, Poplin E, Tap WD, Carmona A, Yonemoto L, et al. J Clin Oncol 2008 26 Suppl abstr 3509
15. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Lancet 2008 372 9637 449 456 10.1016/S0140-6736(08)61039-9 18653228
16. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. J Clin Oncol 2004 22 5 909 918 10.1200/JCO.2004.08. 185 14990647 (Pubitemid 41103603)